Join us at #OCTWestCoast on 11 February at 9am, for a special featured presentation by ICON’s Travis Caudill. Discover if AI is enough and why smarter site identifications still need human-centred strategies. This sessi...

Is AI enough? Artificial intelligence has revolutionised site identification, but it’s not the whole story. At SCOPE 2026, join Travis Caudill, VP – Feasibility, Site Selection & Medical Informatics, as he explores why s...

The development of longer-acting and more potent NUSH receptor agonists, like semaglutide, has helped clarify the link between aberrant glucose metabolism and a range of diseases. Learn how to embrace the multi-indicatio...

To unlock the full value of emerging multi-indication therapies, developers must adopt strategies that prioritise early cross-functional planning and innovative trial architecture. ICON’s Jack Martin and Alan Baldridge...

Product labelling and promotional materials are the foundation of pharma communication and effective pharmaceutical communications begin with a strategic vision anchored in the product label. Regulatory change often br...

#OCTWestCoast will be returning to Burlingame for the 18th annual event on 11-12 February. Pass by booth \#79 and engage in an insightful discussion with ICON Biotech’s professionals regarding the latest challenges and s...

On January 5th, 2026, on the occasion of the visit of Irish Prime Minister Mr. Micheál Martin to China, ICON China team attended a business dinner hosted by the Irish government in Beijing. The event was held at the join...

With over 10,000 journals and conferences to consider it’s an important question to answer. There are 50+ accessible points of metadata to use in focusing your selection for a publishing source. Schedule a demo to learn ...

Potent and long-lasting incretin receptor agonists like GLP-1 RAs target the molecular mechanisms underlying glucose metabolism. Learn why these therapies are ushering in a new era of multi-indication drug development in...

Therapeutic developers can aid control of the HIV epidemic by creating simpler, longer-acting prevention methods that perform better in real-world settings. ICON's whitepaper details these advances and best practices for...

Continuing our series of articles discussing managing risk for medical devices, ICON’s regulatory expert Jeremy Tinkler turns his focus on the biological risk estimate and looks into the logical basis for the use of comp...

Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to si...